

AD_____

Award Number: DAMD17-99-1-9274

TITLE: A Controlled Study Using Acupuncture as an Adjuvant to
Treat Chemotherapy-Induced Nausea and Vomiting

PRINCIPAL INVESTIGATOR: Lixing Lao, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Maryland
Baltimore, Maryland 21201

REPORT DATE: September 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20020717 056

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 2001	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 00 - 31 Aug 01)	
4. TITLE AND SUBTITLE A Controlled Study Using Acupuncture as an Adjuvant to Treat Chemotherapy-Induced Nausea and Vomiting			5. FUNDING NUMBERS DAMD17-99-1-9274	
6. AUTHOR(S) Lixing Lao, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Maryland Baltimore, Maryland 21202 E-Mail:			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) This is a randomized, double blind controlled study designed to assess the effects of electroacupuncture (EA) on nausea and vomiting induced by chemotherapy in cancer patients. The primary aim of this study is to evaluate the usefulness of EA as an adjuvant on N/V in chemotherapy patients who do not respond to conventional antiemetics. Seventy-five outpatients will be recruited from the University of Maryland Baltimore (UMB) Cancer Center who have shown refractory to 5-HT ₃ antiemetic and randomized into three treatment groups (n=25 per group): (1) EA: 10 hz, 10 min, (2) EA: 100 Hz, 10 min, and (3) a sham acupuncture control group. Research team personnel are in place and recruitment began in January 2000. As of August 31, 2001, 101 patients had been screened, 18 judged as eligible, and 10 have consented to go on the protocol and have now completed the study. The study has experienced difficulty with obtaining sufficient numbers of patients due to the low prevalence of nausea and vomiting among the chemotherapy patients at the UMB Cancer Center. For this reason an amendment is being submitted to the IBB (and permission will be requested from the DOD) to extend the study into the Cancer Center's Bone Transplant Unit, which (pending approval) will begin in November, 2001.				
14. SUBJECT TERMS Breast Cancer, Electroacupuncture, Chemotherapy, Nausea, Vomiting, Quality of Life				15. NUMBER OF PAGES 5
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified		20. LIMITATION OF ABSTRACT Unlimited

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5
References.....	5
Appendices.....	5

INTRODUCTION

Nausea and vomiting (N/V) are significant side effects of cancer chemotherapy which can both affect a patient's quality of life and compromise a physician's ability to deliver adequate doses of effective chemotherapy. The purposes of this study are: 1) to evaluate the effectiveness of EA as an adjunctive therapy for minimizing nausea and vomiting caused by chemotherapy; 2) to compare the effectiveness of two protocols of EA on N/V; and 3) to measure the usefulness of EA in improving the general quality of life of cancer patients. This is a randomized, double blind controlled clinical trial with independent assessment of the effect of Electroacupuncture (EA) on nausea and vomiting induced by chemotherapy in patients who do not respond to 5-HT₃ antiemetics. The specific aims of this study are three-fold: 1) to evaluate the usefulness of EA as an adjuvant on N/V in chemotherapy patients who do not respond to 5-HT₃ antiemetics; 2) to compare the effectiveness of two protocols of EA on N/V; and 3) to document the benefit of EA on improving the general quality of life of cancer patients. Seventy five outpatients recruited from Cancer Center, UMB, who have shown refractory to 5-HT₃ antiemetic, will be randomized into three treatment groups (n=25 per group): treatment group I (EA: 10 Hz, 10 min), treatment group II (EA: 100 Hz, 10 min), and sham control group.

BODY

During the first 3 months of the study, the research personnel were hired, including research nurses and acupuncturists. Several research team meetings with the PI and co-investigators, physicians and nurses in the Cancer Center, the research coordinator, and the biostatistician have been held. Patient recruitment began in January 2000. As of August 31, 2001 there have been 101 patients screened for the study. Of the 101 screened, 18 patients were eligible. Ten of the 18 eligible patients have consented to go on protocol and have completed the study. Of the eight eligible patients who chose not to participate, one lived at too great of a distance and was unwilling to travel to the University for the additional appointments necessary for the study, one reported that she was soon to have additional surgery and did not wish to participate, and 10 gave no specific reason for not participating other than they were not interested. Complete data have been obtained from the 10 participating patients and the procedures appear to be working quite well, although due to the low enrollment (ten subjects total) no analyses have been performed to date. No subjects have withdrawn and no serious adverse events due to acupuncture treatment have been observed.

The study continues to experience difficulty with obtaining sufficient recruitment. An amendment requesting Institutional Review Board (IRB) permission to expand the eligibility criteria to include chemotherapy patients who are suffering from cancer other than breast cancer was approved by the UM IRB and the Department of Defense, but unfortunately this did not solve the problem. We have consequently received permission to use patients within the University of Maryland Bone Marrow Transplant Center and are currently pursuing IRB permission to include these patients. When this is obtained, we will request permission from the Department of Defense to change the protocol slightly to incorporate this change, since this center is an inpatient facility involving extremely aggressive chemotherapy and a sufficiently large patient population to allow us to finish the study.

KEY RESEARCH ACCOMPLISHMENTS

- Study research personnel have been hired
- Patient recruitment has begun
- Permission to recruit patients in the UMB Bone Marrow Transplant Center has been obtained and a protocol amendment has been submitted to the UMB IRB.

REPORTABLE OUTCOMES

NA

CONCLUSIONS:

This is an on-going study to investigate the effect of Electroacupuncture (EA) on nausea and vomiting induced by chemotherapy in the cancer patients who do not respond to conventional antiemetics. Research team personnel have been hired. Patient recruitment began in January 2000. However, the patient enrollment has been unexpected slow. This is partially due to relatively small breast cancer patient pool at the UMB Cancer Center. An amendment requesting IRB permission to expand the eligibility criteria to include chemotherapy inpatients in the UMB Bone Marrow Transplant Center has been submitted. The expanded recruitment procedure will begin in Nov. 2000. It is hoped that by expanding the pool of participants the study will have a sufficient number of participants to complete the project.

REFERENCES: NA

APPENDICES : NA